These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36595379)

  • 1. Maximizing Glycemic Benefits of Using Faster Insulin Formulations in Type 1 Diabetes: In Silico Analysis Under Open- and Closed-Loop Conditions.
    Diaz C JL; Colmegna P; Breton MD
    Diabetes Technol Ther; 2023 Apr; 25(4):219-230. PubMed ID: 36595379
    [No Abstract]   [Full Text] [Related]  

  • 2. Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed
    Grosman B; Wu D; Parikh N; Roy A; Voskanyan G; Kurtz N; Sturis J; Cohen O; Ekelund M; Vigersky R
    Comput Methods Programs Biomed; 2021 Jun; 205():106087. PubMed ID: 33873075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid Closed-Loop Control with Ultrarapid Lispro Compared with Standard Insulin Aspart and Faster Insulin Aspart: An In Silico Study.
    Lachal S; Tourki Y; Franc S; Huneker E; Charpentier G; Benhamou PY
    J Diabetes Sci Technol; 2023 Jan; 17(1):176-185. PubMed ID: 34658265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
    Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
    Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study.
    Boughton CK; Hartnell S; Thabit H; Poettler T; Herzig D; Wilinska ME; Ashcroft NL; Sibayan J; Cohen N; Calhoun P; Bally L; Mader JK; Evans M; Leelarathna L; Hovorka R
    Diabetes Obes Metab; 2021 Jun; 23(6):1389-1396. PubMed ID: 33606901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of faster-acting aspart with insulin aspart under conditions mimicking underestimation or missed meal boluses in type 1 diabetes using closed-loop insulin delivery.
    Thabit H; Mubita W; Rubio J; Karuppan M; Schofield J; Willinska ME; Hovorka R; Leelarathna L
    Diabetes Obes Metab; 2023 Apr; 25(4):1121-1124. PubMed ID: 36514847
    [No Abstract]   [Full Text] [Related]  

  • 7. Fast-Acting Insulin Aspart Use with the MiniMed
    Hsu L; Buckingham B; Basina M; Ekhlaspour L; von Eyben R; Wang J; Lal RA
    Diabetes Technol Ther; 2021 Jan; 23(1):1-7. PubMed ID: 32520594
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjusting Therapy Profiles When Switching to Ultra-Rapid Lispro in an Advanced Hybrid Closed-Loop System: An in Silico Study.
    Colmegna P; Diaz C JL; Garcia-Tirado J; DeBoer MD; Breton MD
    J Diabetes Sci Technol; 2024 May; 18(3):676-685. PubMed ID: 36424765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
    Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
    Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes.
    Svehlikova E; Mursic I; Augustin T; Magnes C; Gerring D; Jezek J; Schwarzenbacher D; Ratzer M; Wolf M; Howell S; Zakrzewski L; Urschitz M; Tschapeller B; Gatschelhofer C; Feichtner F; Lawrence F; Pieber TR
    Diabetes Care; 2021 Feb; 44(2):448-455. PubMed ID: 33328285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable Glucose Control with Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System During Exercise.
    Morrison D; Zaharieva DP; Lee MH; Paldus B; Vogrin S; Grosman B; Roy A; Kurtz N; O'Neal DN
    Diabetes Technol Ther; 2022 Feb; 24(2):93-101. PubMed ID: 34524022
    [No Abstract]   [Full Text] [Related]  

  • 12. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
    Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
    CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fully Closed-Loop Glucose Control Compared With Insulin Pump Therapy With Continuous Glucose Monitoring in Adults With Type 1 Diabetes and Suboptimal Glycemic Control: A Single-Center, Randomized, Crossover Study.
    Boughton CK; Hartnell S; Lakshman R; Nwokolo M; Wilinska ME; Ware J; Allen JM; Evans ML; Hovorka R
    Diabetes Care; 2023 Nov; 46(11):1916-1922. PubMed ID: 37616583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: preliminary studies in Padova and Montpellier.
    Bruttomesso D; Farret A; Costa S; Marescotti MC; Vettore M; Avogaro A; Tiengo A; Dalla Man C; Place J; Facchinetti A; Guerra S; Magni L; De Nicolao G; Cobelli C; Renard E; Maran A
    J Diabetes Sci Technol; 2009 Sep; 3(5):1014-21. PubMed ID: 20144414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies.
    Wilinska ME; Budiman ES; Taub MB; Elleri D; Allen JM; Acerini CL; Dunger DB; Hovorka R
    J Diabetes Sci Technol; 2009 Sep; 3(5):1109-20. PubMed ID: 20144424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Faster and Standard Insulin Aspart During Fully Closed-Loop Insulin Delivery in Type 2 Diabetes.
    Herzig D; Dehais J; Prost JC; Nakas CT; Stettler C; Bally L; Hovorka R
    Diabetes Technol Ther; 2020 Sep; 22(9):691-696. PubMed ID: 31999478
    [No Abstract]   [Full Text] [Related]  

  • 17. Short-term fully closed-loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes.
    Bally L; Herzig D; Ruan Y; Wilinska ME; Semmo M; Vogt A; Wertli MM; Vogt B; Stettler C; Hovorka R
    Diabetes Obes Metab; 2019 Dec; 21(12):2718-2722. PubMed ID: 31464063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Two Different Insulin Formulations on Postprandial Hyperglycemia after High and Low Glycemic-Index Meal in Type 1 Diabetes.
    Cutruzzolà A; Parise M; Fiorentino R; Romano A; Molinaro V; Gnasso A; Di Molfetta S; Irace C
    Nutrients; 2022 Aug; 14(16):. PubMed ID: 36014822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hybrid Closed-Loop with Faster Insulin Aspart Compared with Standard Insulin Aspart in Very Young Children with Type 1 Diabetes: A Double-Blind, Multicenter, Randomized, Crossover Study.
    Ware J; Allen JM; Boughton CK; Cezar A; Hartnell S; Wilinska ME; Thankamony A; Deakin M; Leyland H; Phelan K; Thornborough K; Hovorka R
    Diabetes Technol Ther; 2023 Jun; 25(6):431-436. PubMed ID: 36880866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G.
    Weinzimer SA; Bailey RJ; Bergenstal RM; Nimri R; Beck RW; Schatz D; Ambler-Osborn L; Schweiger DS; von dem Berge T; Sibayan J; Johnson ML; Calhoun P; Phillip M;
    Diabetes Technol Ther; 2022 Aug; 24(8):573-582. PubMed ID: 35363054
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.